Literature DB >> 16182129

Toward immunomodulatory and anti-inflammatory properties of statins.

Claire Arnaud1, Vincent Braunersreuther, François Mach.   

Abstract

Over the past decade, a large number of studies reported a prominent role of inflammation and immune response in atherosclerosis. Thus, therapeutic strategies to reduce inflammation could exert beneficial effects in the prevention of atherosclerosis progression. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) have demonstrated their capacity to greatly reduce coronary morbidity and mortality in both primary and secondary intervention trials. Furthermore, originally described as the most efficient drugs to reduce serum cholesterol, recent reports suggest that statins also confer cardiovascular benefits by their ability to modulate immuno-inflammatory processes. This review summarizes in vitro and in vivo evidence of immunomodulatory properties of statins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182129     DOI: 10.1016/j.tcm.2005.07.002

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  25 in total

Review 1.  Alternative macrophage activation and metabolism.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

2.  Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.

Authors:  David Guillén; Federico Cofán; Emilio Ros; Olga Millán; Montse Cofán; Mercè Brunet
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

3.  Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation.

Authors:  Divya Vats; Lata Mukundan; Justin I Odegaard; Lina Zhang; Kristi L Smith; Christine R Morel; Roger A Wagner; David R Greaves; Peter J Murray; Ajay Chawla
Journal:  Cell Metab       Date:  2006-07       Impact factor: 27.287

4.  Does chronic kidney disease modify the association between body mass index and cardiovascular disease risk factors.

Authors:  Nisha Bansal; Eric Vittinghoff; Laura Plantinga; Chi-Yuan Hsu
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

5.  Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses.

Authors:  De-xiu Bu; Margarite Tarrio; Nir Grabie; Yuzhi Zhang; Hiroyuki Yamazaki; George Stavrakis; Elena Maganto-Garcia; Zachary Pepper-Cunningham; Petr Jarolim; Masanori Aikawa; Guillermo García-Cardeña; Andrew H Lichtman
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

6.  Effects of preoperative statin on liver reperfusion injury in major hepatic resection: a pilot study.

Authors:  Shashwat Sarin; Lileswar Kaman; Divya Dahiya; Arunanshu Behera; Bikash Medhi; Yogesh Chawla
Journal:  Updates Surg       Date:  2016-05-10

7.  Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals.

Authors:  Alexandre B Rosendo; Luciana O Lima; Felipe Dal-Pizzol; Silvana Almeida
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

Review 8.  Connexins participate in the initiation and progression of atherosclerosis.

Authors:  Sandrine Morel; Laurent Burnier; Brenda R Kwak
Journal:  Semin Immunopathol       Date:  2009-04-30       Impact factor: 9.623

9.  Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages.

Authors:  Kou-Gi Shyu; Su-Kiat Chua; Bao-Wai Wang; Peiliang Kuan
Journal:  J Biomed Sci       Date:  2009-05-27       Impact factor: 8.410

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.